• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Beta Blockers and Depression: The Controversy Revisited
RESEARCH UPDATE

Beta Blockers and Depression: The Controversy Revisited

November 12, 2020
Sean Ransom, PhD, MP.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Sean Ransom, PhD, MP. Dr. Ransom has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Agustini B et al, J Hum Hypertens 2020 Jan 30

Study Type: Cross-sectional

Antihypertensives are among the world’s most widely prescribed drugs, but many of them impact pathways associated with depression. Beta blockers have long been believed to cause depression, but most of these studies were carried out decades ago and their findings have been inconsistent. Other classes, like angiotensin-receptor blockers, are associated with lower rates of depression, albeit with weaker evidence.

In this multinational study, researchers examined mood outcomes in 14,195 hypertensive adults over age 65 who did not have heart disease. Depressive symptoms were measured with the self-reported Center for Epidemiological Studies-Depression (CESD-10) scale. Each class of antihypertensive drugs was tested against the other classes and against a group of unmedicated hypertensive patients to see whether any class was associated with an increased risk of clinically significant depressive symptoms.

Patients who took beta blockers were more likely to meet or exceed the clinical cutoff score of 8 on the CESD-10 scale, a sign of clinically significant depressive symptoms, than those who took other antihypertensive drugs. Numerically, 13.4% of patients who used beta blockers showed clinical elevations in depression, whereas between 10.2% and 10.5% of patients who used other antihypertensives showed this elevation. Logistic regression analysis showed that this difference was significant, even when controlling for numerous factors that included gender, age, and smoking history. Other classes of antihypertensives, including angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, and calcium-channel blockers, were not associated with depression.

The researchers also compared the beta blockers based on their selectivity for the beta receptor and their lipophilic properties. Lipophilic medications are more likely to cross the blood-brain barrier, and the more lipophilic beta blockers like propranolol and metoprolol were associated with a higher risk of depression than hydrophilic ones like atenolol. Meanwhile, the less selective beta blockers were less depressogenic, a finding that again favors atenolol.

TCPR’s Take
The fact that beta blockers were associated with depression while other antihypertensives were not gives us pause, particularly with the widespread use of propranolol in psychiatry. The increase in depression was small but real in this large geriatric study. Depressed patients with hypertension will do best to avoid beta blockers or, if they must be used, stick with atenolol.
General Psychiatry
KEYWORDS comorbidity depression medical_comorbidities mood disorders psychosomatics
Sean Ransom, PhD, MP.

More from this author
www.thecarlatreport.com
Issue Date: November 12, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Practical Psychotherapy, TCPR, November/December 2020
Is Ramelteon an Effective Hypnotic?
Side Effects of Psychotherapy
Brief Therapy During the Medication Visit
How to Select an SSRI
Metformin ER Recalled Due to Cancer Risk
Chemical Exposures
Beta Blockers and Depression: The Controversy Revisited
Transcranial Direct-Current Stimulation in Depression Reconsidered
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.